BNT-113 is under clinical development by BioNTech and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 35% phase transition success rate ...
Leila Fadel is a national correspondent for NPR based in Los Angeles, covering issues of culture, diversity, and race. Most recently, she was NPR's international correspondent based in Cairo and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback